October 29, 2022

We welcomed the Minister of Health of Iceland

We were humbled to host the Minister of Health of Iceland, Willum Þór Þórsson, at MultiplexDX. Iceland is a true inspiration for us in many ways. How they fought the coronavirus pandemic was phenomenal. Iceland’s Directorate of Health, the government agency that oversees healthcare services, worked hand-in-hand with the private sector, sharing ideas, data, laboratory space, and staff. This robust cooperation allowed Iceland to track the position of the virus and identify practically its every move. The teams even tracked the health of every person who tested positive. What a great story for how Iceland used science and public-private partnerships to combat the pandemic

The Minister of Health took a tour through our labs, from where we developed our Covid-19 tests to where we visualize and sequence tumor tissues for our breast cancer diagnostic test called Multiplex8+. We enjoyed this unique opportunity to discuss our EIC Accelerator cancer research and the importance of cross-sector cooperation.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News